Medroxyprogesterone acetate and Weight loss - a phase IV clinical study of FDA data

Summary:

Weight loss is reported as a side effect among people who take Medroxyprogesterone acetate (medroxyprogesterone acetate), especially for people who are female, 40-49 old, have been taking the drug for 2 - 5 years also take Captopril, and have Endometrial cancer.

The phase IV clinical study analyzes which people have Weight loss when taking Medroxyprogesterone acetate. It is created by eHealthMe based on reports of 12,407 people who have side effects when taking Medroxyprogesterone acetate from the FDA, and is updated regularly.

What is Medroxyprogesterone acetate?

Medroxyprogesterone acetate has active ingredients of medroxyprogesterone acetate. It is often used in birth control. eHealthMe is studying from 12,600 Medroxyprogesterone acetate users. Check the latest studies of Medroxyprogesterone acetate.

What is Weight loss?

Weight loss is found to be associated with 1,449 drugs and 2,293 conditions by eHealthMe. Check the latest studies of Weight loss.

On Jul, 23, 2026

12,407 people reported to have side effects when taking Medroxyprogesterone acetate.
Among them, 12 people (0.1%) have Weight loss.

Could Medroxyprogesterone acetate cause Weight loss?

Among these 12 people:

How long have people been on Medroxyprogesterone acetate when they have Weight loss? *

What is the gender of people who have Weight loss when taking Medroxyprogesterone acetate? *

female: 91.67 %
male: 8.33 %

What is the age of people who have Weight loss when taking Medroxyprogesterone acetate? *

What are other drugs people take besides Medroxyprogesterone acetate? *

What are other side effects people have besides Weight loss? *

Diabetes: 4 people, 33.33%
Hepatic Function Abnormal: 4 people, 33.33%
Diabetic Neuropathy (neuropathic disorders that are associated with diabetes mellitus): 4 people, 33.33%
Hyperlipidaemia (presence of excess lipids in the blood): 4 people, 33.33%
High Blood Pressure: 4 people, 33.33%
Weight Increased: 3 people, 25.00%
Joint Pain: 3 people, 25.00%
Blood Corticotrophin Decreased: 3 people, 25.00%
Blood Cortisol Decreased: 3 people, 25.00%
Type 2 Diabetes: 3 people, 25.00%

What are the existing conditions these people have? *

Neuropathy Peripheral (surface nerve damage): 4 people, 33.33%
Endometrial Cancer: 4 people, 33.33%
Atherosclerosis (disorder of the arteries): 3 people, 25.00%
Joint Pain: 3 people, 25.00%
Eczema (patches of skin become rough and inflamed, with itching and bleeding blisters): 3 people, 25.00%
Seizures (abnormal excessive or synchronous neuronal activity in the brain): 1 person, 8.33%
Heavy Or Prolong Menstrual Bleeding: 1 person, 8.33%
Asthma: 1 person, 8.33%
Constipation: 1 person, 8.33%
Epilepsy (common and diverse set of chronic neurological disorders characterized by seizures): 1 person, 8.33%

* Approximation only. Some reports may have incomplete information.

Do you take Medroxyprogesterone acetate and have Weight loss?

- Check whether Weight loss is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Medroxyprogesterone acetate:

Medroxyprogesterone acetate (12,600 reports)

Weight loss treatments and more:

Weight loss (62,430 reports)

Browse all side effects of Medroxyprogesterone acetate:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Weight loss:

Weight loss (1,449 drugs)

Browse all the conditions that are associated with Weight loss:

Weight loss (2,293 conditions)

Related publications that referenced our studies

Bahall M, Reyes AJ, Ramcharan K, Hosein N, Seegobin K, Bahall K, Sharma H, Dhansingh S, Mahabir A, "Neuro-ophthalmological manifestations after intramuscular medroxyprogesterone: a forme fruste of idiopathic intracranial hypertension?", Neurology international, 2016 Sep .
Bahall M, Reyes AJ, Ramcharan K, Hosein N, Seegobin K, Bahall K, Sharma H, Dhansingh S, Mahabir A, "Neuro-ophthalmological manifestations after intramuscular medroxyprogesterone: a forme fruste of idiopathic intracranial hypertension?", Neurology international, 2016 Sep .

How the study uses the data?

The study uses data from the FDA. It is based on medroxyprogesterone acetate (the active ingredients of Medroxyprogesterone acetate) and Medroxyprogesterone acetate (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.